Snail Fever Vaccine Reaches First Human Clinical Trial
Long journey to prevent major tropical disease is worth the wait

Participant in clinical trial receives world’s first-ever injection of SchistoShield
After decades of hard work, a preventative vaccine for major tropical disease schistosomiasis has reached a Phase 1 clinical trial, providing a dose for the first healthy human volunteer and paving the way into a better future for the 74 countries and nearly one billion people currently threatened by this disease.
Afzal A. Siddiqui, Ph.D., Grover E. Murray Distinguished Professor with Texas Tech University Health Sciences Center (TTUHSC) School of Medicine, served as lead researcher and invented the schistosomiasis vaccine, called SchistoShield®. This vaccine was brought about by PAI Life Sciences, a biotechnology company specializing in translational research for neglected tropical diseases.
According to Siddiqui, it is the result of many years of hard work and research.

Afzal A. Siddiqui, Ph.D.
“It has been 30 years of a bumpy ride at a snail’s pace to bring SchistoShield® vaccine for snail fever [schistosomiasis] to first in human clinical trials,” said Siddiqui.
Schistosomiasis (or ‘snail fever’) is a disease caused by parasitic flatworms predominantly found in sub-Saharan Africa, Middle East, Southeast Asia and the Caribbean. These worms reach humans through the skin when it comes into contact with contaminated water. Symptoms of schistosomiasis include abdominal pain, diarrhea and blood in stools and/or urine. With the potential to cause long-term liver damage, kidney failure and death, a clinically proven vaccine could change the course of the future for millions.
“Development of a vaccine that is effective against geographically distinct forms of schistosomiasis is essential to make a meaningful impact in global reduction of disease burden,” said Siddiqui. “A low-cost, effective vaccine for schistosomiasis would greatly aid in the fight against this debilitating disease. The significance of successful clinical trials is clear in that an approved, effective, deployable vaccine for this disease would impact as many as one billion people in 74 countries throughout the world.”
In May of this year, TTUHSC achieved Carnegie Classification® status for Special Focus Four-Year Research Institutions.
The clinical trial will evaluate the safety and the immunogenicity of PAI Life Sciences’s SchistoShield® vaccine in 45 healthy adults between the ages of 18 and 55, and is sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Related Stories
TTUHSC Amarillo Awarded $50,000 Grant for Cutting-Edge Cancer Research
TTUHSC in Amarillo has received a $50,000 grant from the Harrington Cancer and Health Foundation to support groundbreaking cancer research led by Hiranmoy Das, Ph.D.
TTUHSC Researchers to Study Gene’s Role in Prostate Cancer Metastasis
With support from a three-year, $1.85 million grant, Srinivas Nandana, Ph.D., and co-investigator Manisha Tripathi, Ph.D., from the Department of Cell Biology and Biochemistry at the TTUHSC School of Medicine will investigate the role of TBX2.
TTUHSC Researcher Receives National Award
The AACR presented its Minority-Serving Institution Faculty Scholar in Cancer Research Award to TTUHSC Associate Professor Duke Appiah, Ph.D., MPH, at the AACR 2025 Annual Meeting in Chicago recently.
Recent Stories
Texas Tech University Health Sciences Center Earns SACSCOC Recognition
TTUHSC has received a clean bill of health from the regional accrediting body, the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), following a Fifth-Year Interim Review by a committee from peer institutions.
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
TTUHSC Amarillo Awarded $50,000 Grant for Cutting-Edge Cancer Research
TTUHSC in Amarillo has received a $50,000 grant from the Harrington Cancer and Health Foundation to support groundbreaking cancer research led by Hiranmoy Das, Ph.D.